Cargando…

Impact of the Family and Household Environment on Pediatric Atopic Dermatitis in Japan

Pediatric atopic dermatitis (AD) can negatively impact the family quality of life (QoL). We report data from the real-world Epidemiology of Children with Atopic Dermatitis Reporting on their Experience (EPI-CARE) study in Japanese pediatric patients, focusing on disease impact on family QoL. Childre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saeki, Hidehisa, Ohya, Yukihiro, Nawata, Hisakatsu, Arima, Kazuhiko, Inukai, Miho, Rossi, Ana B., Bego-Le-Bagousse, Gaelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145633/ https://www.ncbi.nlm.nih.gov/pubmed/37109324 http://dx.doi.org/10.3390/jcm12082988

Ejemplares similares

Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: 2-Year Interim Results from the Phase 3 Rising Up Study
por: Katoh, Norito, et al.
Publicado: (2022)

Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS‐J): Baseline characteristics, treatment history and disease burden
por: Katoh, Norito, et al.
Publicado: (2019)

Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
por: Kuznik, Andreas, et al.
Publicado: (2017)

The Roles of Sex Hormones in the Course of Atopic Dermatitis
por: Kanda, Naoko, et al.
Publicado: (2019)

Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis
por: SILVERBERG, Jonathan I., et al.
Publicado: (2021)

Serum 25-Hydroxyvitamin D Concentrations and Atopic Dermatitis in Early Childhood: Findings from the Japan Environment and Children’s Study
por: Yang, Limin, et al.
Publicado: (2021)

Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis
por: Yosipovitch, Gil, et al.
Publicado: (2021)

Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use
por: DELEURAN, Mette, et al.
Publicado: (2021)

A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis
por: Katoh, Norito, et al.
Publicado: (2021)

Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study
por: Kimball, Alexa B., et al.
Publicado: (2023)

A Randomized, Open-Label, Multicenter Trial of Topical Tacrolimus for the Treatment of Pruritis in Patients with Atopic Dermatitis
por: Takeuchi, Satoshi, et al.
Publicado: (2012)

Difamilast Ointment in Japanese Adult and Pediatric Patients with Atopic Dermatitis: A Phase III, Long-Term, Open-Label Study
por: Saeki, Hidehisa, et al.
Publicado: (2022)

Evaluation of standard treatments for managing adult Japanese patients with inadequately controlled moderate‐to‐severe atopic dermatitis: Two‐year data from the ADDRESS‐J disease registry
por: Katoh, Norito, et al.
Publicado: (2022)

The Eosinophil-to-Lymphocyte Ratio Acts as an Indicator for Improvement of Clinical Signs and Itch by Upadacitinib Treatment in Atopic Dermatitis
por: Hagino, Teppei, et al.
Publicado: (2023)

Effectiveness and Safety of Upadacitinib in Combination with Topical Corticosteroids in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
por: Hagino, Teppei, et al.
Publicado: (2023)

Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials
por: Silverberg, Jonathan I., et al.
Publicado: (2023)

Current status of atopic dermatitis in Japan
por: Furue, Masutaka, et al.
Publicado: (2011)

Publisher Correction to: Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials
por: Silverberg, Jonathan I., et al.
Publicado: (2023)

Health‐care resource use and current treatment of adult atopic dermatitis patients in Japan: A retrospective claims database analysis
por: Igarashi, Atsuyuki, et al.
Publicado: (2019)

Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials
por: Katoh, Norito, et al.
Publicado: (2022)

The Role of the Environment and Exposome in Atopic Dermatitis
por: Stefanovic, Nicholas, et al.
Publicado: (2021)

Long‐term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis
por: Nakagawa, Hidemi, et al.
Publicado: (2019)

Proactive versus Rank-Down Topical Corticosteroid Therapy for Maintenance of Remission in Pediatric Atopic Dermatitis: A Randomized, Open-Label, Active-Controlled, Parallel-Group Study (Anticipate Study)
por: Kamiya, Koji, et al.
Publicado: (2022)

Season of birth and atopic dermatitis in early infancy: results from the Japan Environment and Children’s Study
por: Tsuchida, Akiko, et al.
Publicado: (2023)

The association between constipation and subsequent risk of atopic dermatitis in children: the Japan Environment and Children’s Study
por: Takano, Yoshihiko, et al.
Publicado: (2023)

Current and Emerging Strategies to Inhibit Type 2 Inflammation in Atopic Dermatitis
por: Haddad, El-Bdaoui, et al.
Publicado: (2022)

Dissemination of atopic dermatitis and food allergy information to pregnant women in an online childbirth preparation class
por: Inuzuka, Yusuke, et al.
Publicado: (2021)

Growth analysis among adolescents with moderate-to-severe atopic dermatitis receiving upadacitinib in combination with topical corticosteroids in Japan: A case study series from a phase 3, randomized, controlled trial (Rising Up)
por: Tanaka, Toshiaki, et al.
Publicado: (2022)

Pharmacokinetics, pharmacodynamics, and exposure–efficacy of dupilumab in adults with atopic dermatitis
por: Kamal, Mohamed A., et al.
Publicado: (2022)

Phenotypes of atopic dermatitis up to 36 months of age by latent class analysis and associated factors in Japan
por: Arima, Takayasu, et al.
Publicado: (2022)

Phase 2, randomized, double‐blind, placebo‐controlled, 4‐week study to evaluate the safety and efficacy of OPA‐ 15406 (difamilast), a new topical selective phosphodiesterase type‐4 inhibitor, in Japanese pediatric patients aged 2–14 years with atopic dermatitis
por: Saeki, Hidehisa, et al.
Publicado: (2019)

The ability of biomarkers to assess the severity of atopic dermatitis
por: Nakahara, Takeshi, et al.
Publicado: (2023)

Atopic dermatitis
por: Werfel, Thomas
Publicado: (2011)

Atopic dermatitis
por: Watson, Wade, et al.
Publicado: (2011)

Atopic dermatitis
por: Kapur, Sandeep, et al.
Publicado: (2018)

Atopic dermatitis
por: Galli, Elena, et al.
Publicado: (2020)

Is Dupilumab as Effective in Intrinsic Atopic Dermatitis as It Is in Extrinsic Atopic Dermatitis?
por: Gelato, Federica, et al.
Publicado: (2023)

Impact of Patient and Physician Disconnect on Satisfaction with Treatment for Atopic Dermatitis in Japan
por: Wang, Chaochen, et al.
Publicado: (2022)

Impact of Atopic Dermatitis on Patients and their Partners
por: MISERY, Laurent, et al.
Publicado: (2023)

Atopic dermatitis: allergic dermatitis or neuroimmune dermatitis?
por: Gaspar, Neide Kalil, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_m96rf86lkqr0b87sj0t6s35vi6